Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology

This page shows the latest Novartis Oncology news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters radioligand therapy pipeline with new licence agreement

Novartis bolsters radioligand therapy pipeline with new licence agreement

We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. ... We believe working across multiple approaches is the key to reimagining cancer care,” said Susanne Schaffert, president, Novartis Oncology.

Latest news

  • Novartis plans inclisiran trial in the UK Novartis plans inclisiran trial in the UK

    In attendance was Health Secretary Matt Hancock, who formally opened the new Novartis HQ. ... Pictured left to right: Vas Narasimhan (chief executive officer, Novartis), Mari Scheiffele (general manager UK &Ireland, Novartis Oncology), Health Secretary

  • Rival Novartis, Merck drugs square up on rare lung cancer at ASCO Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

    An inflection point for MET-inhibitor class. Novartis and Merck KGaA have both reported phase 2 results with drugs designed to treat a rare form of non-small cell lung cancer ... Novartis’ capmatinib and Merck’s tepotinib both target the

  • One hit, one miss as FDA panel votes on Daiichi’s cancer drugs One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

    Novartis’ Rydapt (midostaurin) was the first FLT3 inhibitor to reach the market in 2017, and is used alongside chemotherapy for newly-diagnoses FLT3-positive AML. ... The Japanese company has plenty of other candidates in its emerging oncology pipeline

  • Alcon spun off, leaner Novartis raises profit forecast Alcon spun off, leaner Novartis raises profit forecast

    Expects three new launches in 2019. Novartis has posted a 7% increase in sales in the first quarter, and has increased its profit forecasts for the year. ... etanercept). As with most big pharma companies, oncology is a key focus for Novartis, and the

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    said Mari Scheiffele (pictured below), General Manager of Novartis Oncology UK &Ireland. ... Worldwide, Gilead has opened up a lead on Novartis, which confirmed last year that it was struggling with limited manufacturing capacity to produce the synthetic

More from news
Approximately 4 fully matching, plus 105 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    Novartis created Novartis Oncology in 2016 and Pfizer formed several new business units including specialty care,  rare diseases and oncology. ... Novartis/AveXis, are all recent examples of larger companies that have expanded their pipelines in this way

  • Charting a course for expansion Charting a course for expansion

    David was until recently the head of Baxalta's oncology division, whose formation he led, guiding it through a series of acquisitions and partnering deals. ... Doing so was the latest move in a 25-year pharma career that has also encompassed stints at

  • Choosing destiny Choosing destiny

    For instance, if Novo Nordisk designs a secular grail model by combining IBM's Watson with its own therapies, it will be different from, for example, Novartis' secular grail model combining ... immuno-oncology and companion diagnostics.

  • Deal Watch June 2016 Deal Watch June 2016

    Protein engineering - towards enhanced biologics. Also active in immuno-oncology, Novartis signed a broad collaboration and licence agreement with Xencor worth a potential $2.56bn covering two bispecific, tumour targeting antibodies, ... Tiered low

  • Deal Watch May 2016 Deal Watch May 2016

    Not under pressure as are GSK and Pfizer, Novartis announced the separation of its pharmaceuticals division into two business units: Novartis Oncology and Novartis Pharmaceuticals. ... The pharmaceuticals company will include Novartis' other interests in

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals

    Coughlin is a trained oncologist and immunologist with seasoned experience in developing oncology therapeutics. ... This includes serving as executive director of oncology clinical development at Novartis, and asset team leader in early clinical

  • New hires at Bristol-Myers Squibb, Acceleron and FerGene New hires at Bristol-Myers Squibb, Acceleron and FerGene

    Backstrom initially joined Celgene in 2008 as vice president, clinical R&D, with a focus on haematology and oncology. ... He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at

  • Pfizer’s Elizabeth Barrett joins Novartis as its oncology head Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

    She succeeds Bruno Strigini who retires. Novartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland. ... Prior to her time with Pfizer, Barrett held roles with Cephalon andchief executive

  • Novartis Oncology head Bruno Strigini to retire Novartis Oncology head Bruno Strigini to retire

    The head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry. ... Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements.

  • Rainer Boehm and Hervé Hoppenot join Cellectics board Rainer Boehm and Hervé Hoppenot join Cellectics board

    He said: “Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of its patients. ... Prior to joining Incyte, Hoppenot was the president of Novartis Oncology and has several senior roles with with

More from appointments
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics